Company Registration No. 08312703 (England and Wales)
Silicon Pharma Limited
Unaudited accounts
for the year ended 31 December 2024
Silicon Pharma Limited
Unaudited accounts
Contents
Silicon Pharma Limited
Company Information
for the year ended 31 December 2024
Company Number
08312703 (England and Wales)
Registered Office
20 Oliver Business Park
Oliver Road
London
NW10 7JB
England
Silicon Pharma Limited
Statement of financial position
as at 31 December 2024
Intangible assets
202,004
88,906
Tangible assets
31,397
39,247
Inventories
125,019
123,523
Cash at bank and in hand
47,173
91,186
Creditors: amounts falling due within one year
(271,874)
(287,148)
Net current assets
125,464
211,008
Total assets less current liabilities
358,865
339,161
Creditors: amounts falling due after more than one year
(297,691)
(319,660)
Provisions for liabilities
Deferred tax
(7,849)
(8,021)
Called up share capital
100
100
Profit and loss account
53,225
11,380
Shareholders' funds
53,325
11,480
For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 25 September 2025 and were signed on its behalf by
Mr C Patel
Director
Company Registration No. 08312703
Silicon Pharma Limited
Notes to the Accounts
for the year ended 31 December 2024
Silicon Pharma Limited is a private company, limited by shares, registered in England and Wales, registration number 08312703. The registered office is 20 Oliver Business Park, Oliver Road, London, NW10 7JB, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention.
The accounts are presented in £ sterling.
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Motor vehicles
20% reducing balance
Computer equipment
20% reducing balance
Intangible fixed assets are measured at cost less accumulated amortisation and any accumulated impairment losses
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the company's accounts. Deferred tax is provided in full on timing differences which result in an obligation to pay more (or less) tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws.
Deferred tax assets and liabilities are not discounted.
Stock have been valued at the lower of cost and estimated selling price less costs to complete and sell.
Silicon Pharma Limited
Notes to the Accounts
for the year ended 31 December 2024
4
Intangible fixed assets
Other
At 31 December 2024
202,004
Other increase/(decrease)
(22,226)
At 31 December 2024
202,004
At 31 December 2023
88,906
The Director of the company considers that the Product licences have infinite useful life and hence development costs are not amortised.
5
Tangible fixed assets
Motor vehicles
Computer equipment
Total
Cost or valuation
At cost
At cost
At 1 January 2024
46,090
16,946
63,036
At 31 December 2024
46,090
16,946
63,036
At 1 January 2024
9,812
13,977
23,789
Charge for the year
7,256
594
7,850
At 31 December 2024
17,068
14,571
31,639
At 31 December 2024
29,022
2,375
31,397
At 31 December 2023
36,278
2,969
39,247
Amounts falling due within one year
Trade debtors
170,851
108,860
Other debtors
54,295
174,587
Silicon Pharma Limited
Notes to the Accounts
for the year ended 31 December 2024
7
Creditors: amounts falling due within one year
2024
2023
Trade creditors
152,382
152,982
Taxes and social security
6,229
1,397
Loans from directors
109,620
123,487
8
Creditors: amounts falling due after more than one year
2024
2023
Bank loans
266,445
283,932
Obligations under finance leases and hire purchase contracts
31,246
35,728
9
Average number of employees
During the year the average number of employees was 2 (2023: 2).